{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:35:55Z","timestamp":1785551755018,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies (mAbs) are increasingly being launched on the German market and account for a growing share of total drug costs every year. In 2021 alone, eleven monoclonal antibodies were among the 30 best-selling drugs, accounting for 9.91% of total drug costs. In contrast, a considerable additional benefit of the newly introduced monoclonal antibodies is not predominantly demonstrable. Therefore, our objective was to analyze the drug prescriptions and associated costs in comparison to the benefit assessment of the Federal Joint Committee (GBA). This paper analyzes 62 monoclonal antibodies that were approved by the European Medicines Agency in the period from 2010 to 2021 and newly launched on the German market. The data basis is provided by the Drug Prescription Report (AVR) and the Statutory Health Insurance (SHI) Drug Index for outpatients. The SHI index is compiled by the Wissenschaftliches Institut der AOK (WIdO). The GBA provides a further data basis for the assessment of additional benefits. The relevant parameters used for each drug include the number of prescriptions, net costs, defined daily doses (DDD) and costs of the defined daily doses (DDD costs) at the time of the year of approval and as of 2021. There is only a slight correlation between the number of DDDs, prescriptions and net costs of the respective drug and the additional benefit assessed by the GBA. There is a certain correlation between the advertisements in the journal \u201cOncology Research and Treatment\u201d and the drug benefit. In summary, the high costs of monoclonal antibodies cannot be justified by the additional benefit assessed by the GBA, as no overriding significant additional benefit can be proven for the drugs analyzed. More precise regulation of drugs with little or no additional benefit, as well as regulation of the price of drugs with considerable additional benefit, is crucial to ensure a better balance between costs and benefits.<\/jats:p>","DOI":"10.1007\/s00210-026-05201-3","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:54:31Z","timestamp":1775526871000},"page":"13961-13980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Critical analysis of the prescription and evaluation of monoclonal antibodies approved in Germany for the outpatient setting from 2010\u20142021"],"prefix":"10.1007","volume":"399","author":[{"given":"Anna Lena","family":"T\u00f6dter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"5201_CR1","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (2015) Entyvio (Vedolizumab). Arzneimittelkommission der deutschen \u00c4rzteschaft.\u00a0https:\/\/www.akdae.de\/fileadmin\/user_upload\/akdae\/Arzneimitteltherapie\/AVP\/Artikel\/201501\/032.pdf. Accessed 19 Apr 2024"},{"key":"5201_CR2","unstructured":"\u00c4rzte Zeitung (2019) EU-Zulassung f\u00fcr Olaratumab wird widerrufen. \u00c4rzteZeitung.\u00a0https:\/\/www.aerztezeitung.de\/Medizin\/EU-Zulassung-fuer-Olaratumab-wird-widerrufen-255811.html?utm_campaign=SocialMediaShare&utm_source=Story&utm_medium=Sharelink. Accessed 7.5.2025"},{"key":"5201_CR3","unstructured":"Bundestag (2022) Gesetz zur finanziellen Stabilisierung der gesetzlichen Krankenversicherung"},{"key":"5201_CR4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","volume":"36","author":"NI Cherny","year":"2025","unstructured":"Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, Gyawali B, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, De Vries EGE (2025) ESMO-magnitude of clinical benefit scale version 2.0 (ESMO-MCBS v2.0). Ann Oncol 36:866\u2013908. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.006","journal-title":"Ann Oncol"},{"key":"5201_CR5","doi-asserted-by":"crossref","unstructured":"Dami\u00e1n-Blanco et al (2023) Use of monoclonal antibodies in cancer immunotherapy: types and mechanism of action.\u00a0https:\/\/www.scielo.org.mx\/scielo.php?script=sci_arttext_plus&pid=S1665-11462023000300153&lng=pt&tlng=en&nrm=iso. Accessed 13 Nov 2025","DOI":"10.24875\/BMHIM.22000123"},{"key":"5201_CR6","unstructured":"DDD schnell erkl\u00e4rt (2025) Die forschenden Pharma-Unternehmen.\u00a0https:\/\/www.vfa.de\/de\/gesundheit-versorgung\/gesundheitspolitik\/abcgesundheitspolitik\/ddd-schnell-erklaert. Accessed 13 Nov 2025"},{"key":"5201_CR7","unstructured":"European Medicines Agency (2025) Fachinformation Keytruda.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed 01.04.2025"},{"key":"5201_CR8","unstructured":"European Medicines Agency (2021) Portazza Necitumomab. European Medicines Agency.\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/portrazza. Accessed 5.11.2023"},{"key":"5201_CR9","unstructured":"European Medicines Agency (n.d.) Portazza-Fachinformation.\u00a0https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170216137137\/anx_137137_de.pdf. Accessed 14 Nov 2025"},{"key":"5201_CR10","unstructured":"European Medicins Agency (2025) Fachinformation Opdivo.\u00a0https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/opdivo-epar-product-information_de.pdf. Accessed 13 Nov 2025"},{"key":"5201_CR11","unstructured":"European Society for Medical Oncology (n.d.) ESMO-MCBS Scorecard. ESMO.\u00a0https:\/\/www.esmo.org\/guidelines. Accessed 05.07.2025"},{"key":"5201_CR12","unstructured":"European Society for Medical Oncology  (2025) ESMO-magnitude of clinical benefit scale. Website"},{"key":"5201_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","volume":"44","author":"P Fessas","year":"2017","unstructured":"Fessas P, Lee H, Ikemizu S, Janowitz T (2017) A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol 44:136\u2013140. https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.002","journal-title":"Semin Oncol"},{"key":"5201_CR14","unstructured":"Fuchs et al (2012) DDD vs. PDD: Berechnung von Tagestherapiekosten am Beispiel Liraglutid. Monitor-Versorgungsforschung.\u00a0https:\/\/www.monitor-versorgungsforschung.de\/abstract\/ddd-vs-pdd-berechnung-von-tagestherapiekosten-am-beispiel-von-liraglutid\/?cookie-state-change=1763030474637. Accessed 13 Nov 2025"},{"key":"5201_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/s-0034-1397474","volume":"53","author":"Gemeinsame Stellungnahme der Deutschen Gesellschaft f\u00fcr Gastroenterologie","year":"2015","unstructured":"Gemeinsame Stellungnahme der Deutschen Gesellschaft f\u00fcr Gastroenterologie (2015) Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft f\u00fcr Innere Medizin (DGIM) zur Vedolizumab-Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V des G-BA. Z Gastroenterol 53:54\u201358. https:\/\/doi.org\/10.1055\/s-0034-1397474","journal-title":"Z Gastroenterol"},{"key":"5201_CR16","unstructured":"Gemeinsamer Bundesausschuss (n.d.) Ergebnisse der Nutzenbewertung \u2013 Kategorien des Zusatznutzens.\u00a0https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/zusatznutzen\/. Accessed 01 Jan 2022"},{"key":"5201_CR17","unstructured":"Gemeinsamer Bundesausschuss (2009) Verfahrensordnung des Gemeinsamen Bundesausschuss.\u00a0https:\/\/www.g-ba.de\/downloads\/62-492-2905\/VerfO_2022-05-19_iK_2022-08-17.pdf. Accessed 01.09.2022"},{"key":"5201_CR18","unstructured":"GKV Spitzenverband (2026) Fragen und Antworten zu DRG. GKV Spitzenverband.\u00a0https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/krankenhaeuser\/drg_system\/fragen_und_antworten_drg\/fragen_und_antworten_drg.jsp. Accessed 2.8.2026"},{"key":"5201_CR19","unstructured":"Laschet (2017) Leitlinien versus Nutzenbewertung - die Unterschiede sind betr\u00e4chtlich, \u00c4rzteZeitung.\u00a0https:\/\/www.aerztezeitung.de\/Politik\/Leitlinien-versus-Nutzenbewertung-die-Unterschiede-sind-betraechtlich-375707.html. Accessed 13 Nov 2025"},{"key":"5201_CR20","volume-title":"Arzneiverordnungs-Report 2022","author":"W-D Ludwig","year":"2023","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2023) Arzneiverordnungs-Report 2022. Springer Berlin \/ Heidelberg, Berlin, Heidelberg"},{"key":"5201_CR21","doi-asserted-by":"publisher","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (eds) (2022) Arzneiverordnungs-Report 2022. Springer Berlin Heidelberg, Berlin, Heidelberg. https:\/\/doi.org\/10.1007\/978-3-662-66303-5","DOI":"10.1007\/978-3-662-66303-5"},{"key":"5201_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-63825-5","volume-title":"Arzneiverordnungs-Report 2021","author":"W-D Ludwig","year":"2021","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2021) Arzneiverordnungs-Report 2021. Springer-Verlag GmbH"},{"key":"5201_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","volume":"59","author":"JC Moser","year":"2020","unstructured":"Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020) Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol 59:434\u2013437. https:\/\/doi.org\/10.1080\/0284186X.2020.1712473","journal-title":"Acta Oncol"},{"key":"5201_CR24","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00210-023-02475-9","volume":"396","author":"CS Obst","year":"2023","unstructured":"Obst CS, Seifert R (2023) Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany. Naunyn-Schmiedebergs Arch Pharmacol 396:2529\u20132543. https:\/\/doi.org\/10.1007\/s00210-023-02475-9","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"5201_CR25","doi-asserted-by":"crossref","unstructured":"Oncology Research and Treatment (2020) Volume 43 Issue 1-10 Oncology Research and Treatment","DOI":"10.1159\/000510995"},{"key":"5201_CR26","unstructured":"Pharmazeutische Zeitung (2020) Dinutuximab\/Unituxin\/86\/2016. Pharmazeutische Zeitung.\u00a0https:\/\/www.pharmazeutische-zeitung.de\/arzneistoffe\/daten\/2016\/dinutuximabunituxinr862016\/. Accessed 7.5.2025"},{"key":"5201_CR27","unstructured":"Reimbursement Institute (2026) Zusatzentgelt. Reimbursement Institute.\u00a0https:\/\/reimbursement.institute\/glossar\/zusatzentgelt\/. Accessed 2.6.2026"},{"key":"5201_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.healthpol.2014.08.004","volume":"118","author":"J Ruof","year":"2014","unstructured":"Ruof J, Knoerzer D, D\u00fcnne A-A, Dintsios C-M, Staab T, Schwartz FW (2014) Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany. Health Policy 118:242\u2013254. https:\/\/doi.org\/10.1016\/j.healthpol.2014.08.004","journal-title":"Health Policy"},{"key":"5201_CR29","doi-asserted-by":"publisher","unstructured":"Schr\u00f6der H, Th\u00fcrmann PA, Telschow C, Schr\u00f6der M, Busse R (Eds.) (2021) Arzneimittel-Kompass 2021: hochpreisige Arzneimittel - Herausforderung und Perspektiven. Springer, Berlin, Germany [Heidelberg]. https:\/\/doi.org\/10.1007\/978-3-66-63929-0","DOI":"10.1007\/978-3-66-63929-0"},{"key":"5201_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-62168-4","volume-title":"Arzneiverordnungs-Report 2020","author":"U Schwabe","year":"2020","unstructured":"Schwabe U, Ludwig W-D (2020) Arzneiverordnungs-Report 2020. Springer Berlin \/ Heidelberg, Berlin, Heidelberg"},{"key":"5201_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-59046-1","volume-title":"Arzneiverordnungs-Report 2019: aktuelle Daten, Kosten, Trends und Kommentare","author":"U Schwabe","year":"2019","unstructured":"Schwabe U, Paffrath D, Ludwig W-D, Klauber J (2019) Arzneiverordnungs-Report 2019: aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin, Berlin"},{"key":"5201_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-54630-7","volume-title":"Arzneiverordnungs-Report 2017","author":"U Schwabe","year":"2017","unstructured":"Schwabe U, Paffrath D, Ludwig W-D, Klauber J (2017) Arzneiverordnungs-Report 2017. Springer Berlin Heidelberg, Berlin, Heidelberg"},{"key":"5201_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-57386-0","volume-title":"Arzneiverordnungs-Report 2018","author":"U Schwabe","year":"2018","unstructured":"Schwabe U, Paffrath D, Ludwig W-D, Springer-Verlag GmbH (2018) Arzneiverordnungs-Report 2018"},{"key":"5201_CR34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4049\/immunohorizons.2300102","volume":"7","author":"R Singh","year":"2023","unstructured":"Singh R, Chandley P, Rohatgi S (2023) Recent advances in the development of monoclonal antibodies and next-generation antibodies. ImmunoHoriz 7:886\u2013897. https:\/\/doi.org\/10.4049\/immunohorizons.2300102","journal-title":"ImmunoHoriz"},{"key":"5201_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1147488","volume":"14","author":"C-Y Su","year":"2023","unstructured":"Su C-Y, Yan Y-Y, Zhang J-Y, Zhang Y-K, Chen Z-S (2023) Editorial: targeted cancer therapies, from small molecules to antibodies, volume II. Front Pharmacol 14:1147488. https:\/\/doi.org\/10.3389\/fphar.2023.1147488","journal-title":"Front Pharmacol"},{"key":"5201_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2022.03.020","volume":"167","author":"M Torasawa","year":"2022","unstructured":"Torasawa M, Yoshida T, Yagishita S, Shimoda Y, Shirasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y (2022) Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: a propensity-matched real-world analysis. Lung Cancer 167:49\u201357. https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.020","journal-title":"Lung Cancer"},{"key":"5201_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS (2021) Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol 7:e212026. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2026","journal-title":"JAMA Oncol"},{"key":"5201_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1055\/s-2007-963546","volume":"13","author":"J Wasem","year":"2008","unstructured":"Wasem J, Bramlage P (2008) Defined daily doses: ein instrument zur kostensteuerung im gesundheitswesen? Gesundh \u00d6kon Qual Manag 13:38\u201342. https:\/\/doi.org\/10.1055\/s-2007-963546","journal-title":"Gesundh \u00d6kon Qual Manag"},{"key":"5201_CR39","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, WHO Collaborating Centre for Drug Statistics Methodology (2018) Definition und allgemeine \u00dcberlegungen DDD. WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health.\u00a0https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/"},{"key":"5201_CR40","unstructured":"Wissenschaftliches Institut der AOK (2022) ATC-Klassifikation f\u00fcr den deutschen Arzneimittelmarkt. WIdO Wissenschaftliches Institut der AOK.\u00a0https:\/\/www.wido.de\/publikationen-produkte\/arzneimittel-klassifikation\/. Accessed 10.3.2022"},{"key":"5201_CR41","unstructured":"Wissenschaftliches Institut der AOK (n.d.) PharMaAnalyst URL https:\/\/arzneimittel.wido.de\/PharMaAnalyst\/;jsessionid=AA1A8ED40FF27BC8E6CE760E0DF045CD?0. Accessed 04 Apr 2024"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05201-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:34Z","timestamp":1783907014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5201"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05201-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      . The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}